A small prospective COPD study reported numerical decreases in serum MMP-9 with roflumilast alongside clinical improvement (CAT score), although changes did not reach statistical significance-underscoring limited power and substantial biomarker variability [103]. Here, MMP9 is linked to chronic obstructive pulmonary disease.